Atopic dermatitis: new horizons of topical therapy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Atopic dermatitis is a chronic relapsing inflammatory skin disease characterized by intense itching, which significantly reduces the quality of life of patients of any age. This article presents the principles of prevention of exacerbations of the disease and considers the innovative components of agents intended for topical use for the purpose of restoring the hydrolipid mantle, the protective properties of the epidermis, correcting the microbioma, reducing the itching and repairing the damaged epidermis in atopic dermatitis.

Full Text

Restricted Access

About the authors

A. V Michenko

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology of the Moscow Healthcare Department

Email: amichenko@mail.ru
PhD, Leading Researcher at the Department of Clinical Dermatovenereology and Cosmetology

O. V Zhukova

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology of the Moscow Healthcare Department

A. N L’vov

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology of the Moscow Healthcare Department

References

  1. Померанцев О.Н., Потекаев Н.Н. Заболеваемость населения болезнями кожи и подкожной клетчатки как медико-социальная проблема. Клин. дермол. венерол 2013;6:4-6.
  2. Metz M., Wahn U., Gieler U., et al. Chronic pruritus associated with dermatologic disease in infancy and childhood: update from an interdisciplinary group of dermatologists and pediatricians. Pediatr. Allergy Immunol. 2013;24(6):527-39.
  3. Simpson E.L., Bieber T., Eckert L., Wu R., Ardeleanu M., Graham N.M., et al. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. J. Am. Acad. Dermatol. 2016;74(3):491-98.
  4. Chida Y., Steptoe A., Hirakawa N., Sudo N., Kubo C. The effects of psychological intervention on atopic dermatitis. A systematic review and meta-analysis. Int. Arch. Allergy Immunol. 2007;144(1):1-9.
  5. Silverberg J.I., Selected comorbidities of atopic dermatitis: Atopy, neuropsychiatric, and musculoskeletal associations. Clin. Dermatol. 2017;35(4):360-66.
  6. Gandini S., Stanganelli I., Palli D., De Giorgi V., Masala G., Caini S. Atopic dermatitis, naevi count and skin cancer risk: A meta-analysis. J. Dermatol. Sci. 2016;84(2):137-43.
  7. Legendre L., Barnetche T., Mazereeuw-Hautier J., Meyer N., Murrell D., Paul C. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis. J. Am. Acad. Dermatol. 2015;72(6):992-1002.
  8. Morgan T.K., Hanifin J., Mahmood M. Atopic Dermatitis Is Associated With Cervical High Risk Human Papillomavirus Infection. J. Low Genit. Tract. Dis. 2015;19(4):345-49.
  9. Choi E.H., Brown B.E., Crumrine D., Chang S., Man M.Q., Elias R.M., Feingold K.R. Mechanisms by which psychologic stress alters cutaneous permeability barrier homeostasis and stratum corneum integrity. J. Invest. Dermatol. 2005;124(3):587-95.
  10. Aberg K.M., Radek K.A., Choi E.H., et al. Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice. J. Clin. Invest. 2007;117(11):3339-49.
  11. Федеральные клинические рекомендации по ведению больных атопическим дерматитом. Российское общество дерматовенерологов и косметологов. М., 2013.
  12. Melzack R., Wall P.D. Pain mechanisms: a new theory. Science 1965;150:971-79. Mendell L.M. Constructing and deconstructing the gate theory of pain. Pain. 2014;155:210-16.
  13. Duan B., Cheng L., Ma Q. Spinal Circuits Transmitting Mechanical Pain and Itch Neurosci Bull. 2017;1-8.
  14. Burton S.D., Morita R.Y. Effect of catalase and cultural conditions on growth of Beggiatoa. J. Bacteriol. 1964;88:1755-61.
  15. Nelson D.C., Wirsen C.O., Jannasch H.W. Characterization of Large, Autotrophic Beggiatoa spp. Abundant at Hydrothermal Vents of the Guaymas Basin. Appl. Environ Microbiol. 1989;55(11):2909-17.
  16. Mahé Y.F., Martin R., Aubert L., Billoni N., Collin C., Pruche F., Bastien P., Drost S.S., Lane A.T., Meybeck A. Induction of the skin endogenous protective mitochondrial MnSOD by Vitreoscilla filiformis extract. Int. J. Cosmet. Sci. 2006;28(4):277-87.
  17. Mahe Y.F., Perez M.-J., Tacheau C., Fanchon C., Martin R., Rousset F., Seite S. A new Vitreoscilla filiformis extract grown on spa water-enriched medium activates endogenous cutaneous antioxidant and antimicrobial defenses through a potential Toll-like receptor 2/protein kinase C, zeta transduction pathway. Clin. Cosmet. Investing. Dermatol. 2013; 6:191-96.
  18. Mahé Y., Martin R., inventors, L'Oréal Use of a vitreoscilla filiformis lipopolysaccharide fraction as an agent for stimulating the synthesis of antimicrobial skin peptides. Mar 25, 2008. Feb 25, 2009. European patent EP1974720A1. United States patent US2009035294A1.
  19. Martin R. inventor, L'Oréal Lipid A-type compound and composition containing it. Jun 2, 2005. United States patent US2005118118.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies